Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The proprietary CEACAM1 antibodies are having a direct co-stimulatory effect on immune cells in addition to interfering with the CEACAM1-CEACAM mediated check-point blockade.
Products, services, technology
Monoclonal Antibodies directed against CEACAM (Carcinoembryonic Antigen-related Cell Adhesion Molecules)
- https://www.ymmunobio.com
- +41 76 475 96 76
- info@ymmuno.bio
- Dr. Katrin Rupalla, CEO
